198 related articles for article (PubMed ID: 17535973)
1. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population.
Ørsted DD; Bojesen SE; Tybjaerg-Hansen A; Nordestgaard BG
J Exp Med; 2007 Jun; 204(6):1295-301. PubMed ID: 17535973
[TBL] [Abstract][Full Text] [Related]
2. The common germline Arg72Pro polymorphism of p53 and increased longevity in humans.
Bojesen SE; Nordestgaard BG
Cell Cycle; 2008 Jan; 7(2):158-63. PubMed ID: 18256523
[TBL] [Abstract][Full Text] [Related]
3. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population.
Zhu ZZ; Cong WM; Liu SF; Dong H; Zhu GS; Wu MC
World J Gastroenterol; 2005 Jan; 11(2):289-92. PubMed ID: 15633234
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population.
Mostaid MS; Ahmed MU; Islam MS; Bin Sayeed MS; Hasnat A
Tumour Biol; 2014 Oct; 35(10):10309-17. PubMed ID: 25034526
[TBL] [Abstract][Full Text] [Related]
5. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
Cescon DW; Bradbury PA; Asomaning K; Hopkins J; Zhai R; Zhou W; Wang Z; Kulke M; Su L; Ma C; Xu W; Marshall AL; Heist RS; Wain JC; Lynch TJ; Christiani DC; Liu G
Clin Cancer Res; 2009 May; 15(9):3103-9. PubMed ID: 19383811
[TBL] [Abstract][Full Text] [Related]
6. p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a case-control study.
Sümbül AT; Akkız H; Bayram S; Bekar A; Akgöllü E; Sandıkçı M
Mol Biol Rep; 2012 Feb; 39(2):1639-47. PubMed ID: 21607615
[TBL] [Abstract][Full Text] [Related]
7. TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals.
Kodal JB; Vedel-Krogh S; Kobylecki CJ; Nordestgaard BG; Bojesen SE
Sci Rep; 2017 Mar; 7(1):336. PubMed ID: 28336930
[TBL] [Abstract][Full Text] [Related]
8. p53 Arg72Pro polymorphism, adiposity status, and cancer risk: Two case-cohorts within a Japanese prospective study.
Nakano S; Yamaji T; Katagiri R; Sawada N; Inoue M; Tsugane S; Iwasaki M;
Cancer Sci; 2022 Dec; 113(12):4385-4393. PubMed ID: 36083231
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma].
Cao YY; Ge H; Chen LQ; Chen ZF; Wen DG; Li Y; Zhang JH
Ai Zheng; 2007 Oct; 26(10):1052-7. PubMed ID: 17927872
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of the TP53 Arg72Pro single-nucleotide polymorphism and susceptibility to medulloblastoma in a cohort of Brazilian patients.
Carvalho RM; Pinto GR; Yoshioka FK; Lima PD; Souza CR; Guimarães AC; Lamarão LM; Rey JA; Burbano RR
J Neurooncol; 2012 Oct; 110(1):49-57. PubMed ID: 22886512
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.
Horikawa Y; Nadaoka J; Saito M; Kumazawa T; Inoue T; Yuasa T; Tsuchiya N; Nishiyama H; Ogawa O; Habuchi T
Oncol Rep; 2008 Jul; 20(1):49-55. PubMed ID: 18575717
[TBL] [Abstract][Full Text] [Related]
12. p16 gene silencing along with p53 single-nucleotide polymorphism and risk of esophageal cancer in Northeast India.
Das M; Sharma SK; Sekhon GS; Mahanta J; Phukan RK; Jalan BK
Tumour Biol; 2017 May; 39(5):1010428317698384. PubMed ID: 28459370
[TBL] [Abstract][Full Text] [Related]
13. P53 codon 72 polymorphism in bladder cancer--no evidence of association with increased risk or invasiveness.
Törüner GA; Uçar A; Tez M; Cetinkaya M; Ozen H; Ozçelik T
Urol Res; 2001 Dec; 29(6):393-5. PubMed ID: 11828992
[TBL] [Abstract][Full Text] [Related]
14. The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer risk.
Proestling K; Hebar A; Pruckner N; Marton E; Vinatzer U; Schreiber M
PLoS One; 2012; 7(10):e47325. PubMed ID: 23071787
[TBL] [Abstract][Full Text] [Related]
15. P53 Arg72Pro polymorphism in gastric cancer patients.
Gomes de Souza L; Miranda de Lima J; Dale Cotrim Guerreiro da Silva I; Manoukian Forones N
J Gastrointest Cancer; 2009; 40(1-2):41-5. PubMed ID: 19543839
[TBL] [Abstract][Full Text] [Related]
16. p53 Arg72Pro polymorphism confers the susceptibility to endometriosis among Asian and Caucasian populations.
Lao X; Chen Z; Qin A
Arch Gynecol Obstet; 2016 May; 293(5):1023-31. PubMed ID: 26493553
[TBL] [Abstract][Full Text] [Related]
17. Effect of p53 codon 72 polymorphism on the survival outcome in advanced stage cervical cancer patients in India.
Bansal A; Das P; Kannan S; Mahantshetty U; Mulherkar R
Indian J Med Res; 2016 Sep; 144(3):359-365. PubMed ID: 28139534
[TBL] [Abstract][Full Text] [Related]
18. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
19. Effect of p53 Arg72Pro polymorphism on the induction of micronucleus by aflatoxin B1 in in vitro in human blood lymphocytes.
Bayram S; Rencüzoğulları E; Almas AM; Genç A
Drug Chem Toxicol; 2016; 39(3):331-7. PubMed ID: 26738694
[TBL] [Abstract][Full Text] [Related]
20. p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis.
Weng Y; Lu L; Yuan G; Guo J; Zhang Z; Xie X; Chen G; Zhang J
PLoS One; 2012; 7(9):e45820. PubMed ID: 23029260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
